$CHRS News Article - Coherus Presents Phase 1/2 Clinical

New Post Public Reply Private Reply Replies (0) Message Board
whytestocks
222
$CHRS News Article - Coherus Presents Phase 1/2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2023 ESMO Immuno-Oncology Congress https://marketwirenews.com/news-releases/cohe...21860.html

Coherus BioSciences Inc. (CHRS) Stock Research Links

CHRS Board Company Profile Buy Rating Time & Sales News Filings Financials
My Twitter: WhyteStocks